688266.SS SHH
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
1W: -7.2%
1M: -6.5%
3M: -19.3%
YTD: +14.6%
1Y: +3.6%
3Y: +131.0%
5Y: +46.2%
¥110.00 ($16.41)
+3.34 (+3.13%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$813M
+52.5% ▲
5Y CAGR: +96.6%
Gross Profit
$813M
+64.1% ▲
5Y CAGR: +97.4%
Operating Income
-$166M
-6.9% ▼
Net Income
-$161M
-16.6% ▼
EPS (Diluted)
$-0.61
-17.3% ▼
EBITDA
-$123M
-48.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $190M | $302M | $386M | $533M | $813M |
| YoY Growth | +588.2% | +58.8% | +27.8% | +37.9% | +52.5% |
| Cost of Revenue | $7M | $28M | $31M | $38M | $123M |
| Gross Profit | $183M | $275M | $355M | $495M | $813M |
| Gross Margin | 96.3% | 90.9% | 91.9% | 92.9% | 100.0% |
| R&D Expenses | $509M | $498M | $496M | $388M | $0 |
| SG&A Expenses | $214M | $311M | $264M | $327M | $0 |
| Operating Expenses | $642M | $760M | $653M | $650M | $978M |
| Operating Income | -$459M | -$486M | -$298M | -$155M | -$166M |
| Operating Margin | -241.1% | -160.6% | -77.1% | -29.1% | -20.4% |
| Interest Expense | $6M | $15M | $24M | $29M | $25M |
| Income Before Tax | -$465M | -$488M | -$299M | -$155M | -$166M |
| Tax Expense | -$3M | -$2M | -$4M | -$5M | -$6M |
| Net Income | -$451M | -$457M | -$279M | -$138M | -$161M |
| Net Margin | -236.9% | -151.3% | -72.1% | -25.9% | -19.8% |
| EPS (Diluted) | $-1.88 | $-1.91 | $-1.09 | $-0.52 | $-0.61 |
| EBITDA | -$464M | -$486M | -$356M | -$174M | -$123M |
| Shares Outstanding | 240M | 240M | 256M | 265M | 263M |